RxDoctor Payments Data

Wesley McComas

Nurse Practitioner · Springfield, OHNPI 1952888422

Payments from drug & device makers

$8,193in general payments, 2019–2025

Across 488 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$1K
  • Regeneron Healthcare Solutions, Inc.$697
  • Sun Pharmaceutical Industries Inc.$485
  • Novartis$447
  • Sanofi$393
  • plus $4K from 22 others

What the payments were for

  • Food & beverage$7,79895%
  • Education$3955%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,193 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$166,496
Medicare patients
540
Services billed
6,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa12$242,921
Dupixent PenDupilumab35$130,376
OtezlaApremilast16$77,831
Clobetasol Propionate69$3,694
Ketoconazole199$3,154
Fluorouracil35$2,156
Metronidazole32$1,882
Betamethasone Dipropionate56$1,676
Tacrolimus11$1,485
Doxycycline Hyclate79$1,313
Clindamycin Phosphate30$1,178
Triamcinolone Acetonide126$936
Fluocinonide15$920
Nystatin56$611
Ciclopirox18$556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$332$77,83116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Springfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →